# Development of a Biomarker Directed Strategy to Ameliorate Common Toxicities From Conventional Chemotherapy

> **NCT01921998** · — · SUSPENDED · sponsor: **The Christie NHS Foundation Trust** · enrollment: 50 (estimated)

## Conditions studied

- Lymphoma
- Sarcoma

## Interventions

- **PROCEDURE:** Biomarker and health economics

## Key facts

- **NCT ID:** NCT01921998
- **Lead sponsor:** The Christie NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** SUSPENDED
- **Start date:** 2013-10
- **Primary completion:** 2015-11
- **Final completion:** —
- **Target enrollment:** 50 (ESTIMATED)
- **Why stopped:** Trial has been suspended due to lack of resource and staff
- **Last updated:** 2015-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01921998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01921998, "Development of a Biomarker Directed Strategy to Ameliorate Common Toxicities From Conventional Chemotherapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01921998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*